TGA AUSTRALIA updates guidance on Essential Principles for Medical Devices
On November 19, 2025, the Therapeutic Goods Administration (TGA) released an updated version of the guidance “Complying with the Essential Principles.” The document defines the requirements for placing medical devices on the Australian market under the Therapeutic Goods (Medical Devices) Regulations 2002, raising interpretative standards across the entire product lifecycle.
Through 15 Essential Principles (EPs), the guideline outlines the requirements for the design, manufacture, and distribution of safe and effective medical devices. The update introduces additional specifications and clarifications without fundamentally changing the regulatory framework; the most significant developments concern Principle 13 (UDI) and Cybersecurity (EP 12).
Overview of the 15 Essential Principles (EPs)
EP 1: Health and safety of patients and users
Requires that devices be designed and manufactured so as not to compromise the health and safety of patients, users, or third parties. The update places stronger emphasis on a structured risk management approach, extending it across the entire lifecycle—from design and production to decommissioning—and integrating literature analysis and post-market experience.
EP 2: Design and construction
Establishes high standards and emphasizes Total Product Lifecycle (TPLC) management through the quality system. This approach enables continuous improvement processes and incremental updates aligned with the state of the art.
EP 3: Intended performance
Ensures reliable functioning under normal conditions. Additional details have been introduced regarding verification in real-world scenarios and potential malfunctions.
EP 4: Durability
Ensures that device performance remains consistent throughout its intended lifetime. The update requires deeper analysis of material degradation mechanisms and more rigorous validation of storage and transport conditions, including shelf-life testing.
EP 5: Transport and storage
The key change shifts from theoretical resistance assumptions to empirical validation and logistics stress testing. The guidance requires evidence that device performance is not compromised by extreme environmental factors during distribution.
EP 6: Benefit–risk analysis
The guidance now requires a more analytical distinction: each individual variant or model must have its own documentation demonstrating that its specific benefits outweigh residual risks.
EP 7: Chemical, physical, and biological properties
Ensures material safety through high biocompatibility standards. For components of animal origin, formal monitoring of the supply chain is now required to ensure the absence of toxic substances or harmful residues.
EP 8: Infection and microbial contamination risks
Ensures microbiological purity of the device. New clauses (8.10/8.11) introduce stricter protocols for validating sterilization cycles and viral load reduction.
EP 9: Environmental interactions
Ensures that the device is protected from external disturbances. The requirement has been refined with a focus on the robustness of protective enclosures against environmental agents and interference.
EP 10: Measuring functions
Ensures consistent and verifiable measurement accuracy. The update expands examples of validation and requires more analytical stability testing.
EP 11: Protection against radiation
Requires containment of device emissions. The update introduces more specific requirements for shielding systems to maximize the safety of users and patients.
EP 12: Electronic systems and Cybersecurity
Significantly updated with mandatory cybersecurity requirements (EP 12.1). In addition to electrical safety, the principle requires software resilience, protection against malware, and data privacy safeguards.
EP 13: Labelling, Instructions, and Traceability (UDI)
Represents the most significant update with the introduction of new clauses 13.5 and 13.6. The regulation integrates the Unique Device Identification (UDI) system, distinguishing between the Device Identifier (DI) and Production Identifier (PI), with obligations for direct marking and data submission to the AusUDID database.
EP 14: Clinical evidence
Strengthens the requirement to provide clinical data proportionate to the device risk class. The key development is the reinforcement of Post-Market Clinical Follow-up (PMCF), turning evidence generation into a continuous lifecycle monitoring activity.
EP 15: In Vitro Diagnostic (IVD) medical devices
Introduces stricter standards for validating analytical sensitivity and specificity, requiring more detailed metrological traceability of results.
Conclusions: the impact of the new guidance
The evolution of TGA guidance moves toward more stringent requirements across the entire product lifecycle. A clear example is the update of EP 13 (UDI), whose timelines are defined in the Therapeutic Goods (Medical Devices—Unique Device Identification) Regulations 2023. These regulations establish a compliance deadline of July 1, 2026 for Class III and Class IIb devices, including labeling obligations and data submission to the AusUDID database.
In this context, compliance becomes a dynamic process requiring continuous alignment of the Quality Management System (QMS) and the Technical File—from design and production (EP 8 sterility, EP 12 cybersecurity) to post-market surveillance (EP 14). To ensure safe market presence, performing a gap analysis is recommended to assess the robustness of documentation against these updated standards.
>>> Complife provides the expertise needed to interpret these regulatory complexities and maintain compliance.
